Aramic LLC v. Revance Therapeutics, Inc.

UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA 6 ARAMIC LLC, et al., Case No. 21-cv-09585-AMO

Plaintiffs,

ORDER GRANTING DEFENDANTS’

v. MOTION TO DISMISS

REVANCE THERAPEUTICS, INC., et al., Re: Dkt. No. 65 Defendants.

12 This is a securities fraud case about the U.S. Food and Drug Administration’s review of a drug developed by Revance Therapeutics, Inc. (“Revance”). Defendants’ motion to dismiss was heard before this Court on August 10, 2023. Having read the papers filed by the parties and carefully considered their arguments therein and those made at the hearing, as well as the relevant legal authority, the Court hereby GRANTS the motion to dismiss, for the following reasons. I. BACKGROUND1 Plaintiffs Aramic LLC (“Aramic”) and Tang Family Investor Group are stockholders of Defendant Revance Therapeutics, Inc. (“Revance”), who seek to represent purchasers of Revance stock between November 25, 2019, and October 11, 2021 (the “class period”). FAC ¶ 1. Revance is a…